BERWYN, Pa.--(BUSINESS WIRE)--Complexa Inc. today announced the appointment of Elisabeth Leiderman, MD, MBA, as Chief Business Officer. Dr. Leiderman formerly served as Senior Vice President, Head of Corporate Development for Fortress Biotech where she led strategy and oversight for all aspects of corporate development for the company’s 10 subsidiaries.
“Elisabeth is a proven leader with more than 15 years of experience in the biotech, pharmaceutical and healthcare investment banking industries and broad expertise in multiple therapeutic areas, including oncology, cell therapy, gene therapy and neurology,” said Francisco Salva, President and Chief Executive Officer of Complexa. “Her impressive background, coupled with her deep knowledge of value-creating transactions and demonstrated track record of financial leadership, will be invaluable to Complexa as we invest in business growth and advance our pipeline.”
In her role at Complexa, Dr. Leiderman will serve as a strategic leader on the Complexa senior management team, providing input, advice and perspective on all significant business decisions, as well as connecting with external stakeholders, including the investment community. She will be responsible for overseeing business development, financial strategy and operations.
During her tenure with Fortress Biotech, Dr. Leiderman was responsible for managing and leading out-licensing transactions and efforts, in addition to partnering with the head of each subsidiary to build the company and set overall strategy and direction. She also advised on and executed capital raises at the subsidiary levels. Prior to joining Fortress, Dr. Leiderman served as Executive Director, Healthcare Investment Banking for Nomura Securities where she was responsible for originating and executing equity, debt and merger and acquisition (M&A) transactions. She also has held various positions with increasing levels of responsibility within the healthcare investment banking industry at Nomura Securities, Credit Suisse, UBS Investment Bank and Morgan Stanley. She began her career in Medical Affairs at AstraZeneca where she analyzed competitor drugs and emerging industry trends related to the central nervous system.
Dr. Leiderman received her BA degree from University of Pennsylvania and holds an MBA from The Wharton School at University of Pennsylvania. She obtained her MD degree from the Sackler School of Medicine at Tel-Aviv University.
“I am excited to join Complexa and look forward to making significant and meaningful contributions to helping the company deliver upon an unmet need for medicines to treat severe and debilitating fibrotic and inflammatory diseases,” said Dr. Leiderman. “I look forward to the opportunity to come aboard at this pivotal moment of growth.”
Complexa Inc. is a patient-focused, science-driven, clinical stage biopharmaceutical company developing a novel class of compounds, nitrated fatty acids (NFAs), for the safe and effective treatment of debilitating fibrotic and inflammatory diseases. NFAs have demonstrated broad potential to be effective therapeutic agents in multiple disease indications in which oxidative stress, inflammation, fibrosis and/or direct tissue toxicity play significant roles. This class of molecules has the potential to be disease-modifying in many disorders, given the broad activity of NFAs. An experienced consortium of investors, including Andera Partners, HBM Healthcare Investments, JAFCO, New Enterprise Associates (NEA) and Pfizer Venture Investments have committed funding to advance a platform of NFA agents across multiple orphan disease indications. Complexa’s lead candidate, CXA-10, is currently in Phase 2 development for focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). For more information, visit www.complexarx.com.